ALDVI.PA
Price:
$1.74
Market Cap:
$24.64M
Advicenne S.A., a specialty pharmaceutical company, develops and commercializes treatments for nephrology. Its lead product candidate is Sibnayal for the treatment of distal renal tubular acidosis, as well as for the treatment of cystinuria. Advicenne S.A. was founded in 2007 and is headquartered in Paris, France.
Industry
Biotechnology
IPO Date
2017-12-06
Stock Exchange
PAR
Ticker
ALDVI.PA
According to Advicenne S.A.’s latest financial reports and current stock price. The company's current Current Ratio is 0.59. This represents a change of -38.40% compared to the average of 0.96 of the last 4 quarters.
The mean historical Current Ratio of Advicenne S.A. over the last ten years is 4.79. The current 0.59 Current Ratio has changed 1.13% with respect to the historical average. Over the past ten years (40 quarters), ALDVI.PA's Current Ratio was at its highest in in the December 2017 quarter at 18.20. The Current Ratio was at its lowest in in the June 2014 quarter at 0.
Average
4.79
Median
2.38
Minimum
0.37
Maximum
18.20
Discovering the peaks and valleys of Advicenne S.A. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 4.88%
Maximum Annual Current Ratio = 18.20
Minimum Annual Increase = -82.16%
Minimum Annual Current Ratio = 0.37
| Year | Current Ratio | Change |
|---|---|---|
| 2024 | 1.02 | -45.65% |
| 2023 | 1.87 | -37.57% |
| 2022 | 3.00 | 10.05% |
| 2021 | 2.72 | 48.80% |
| 2020 | 1.83 | -57.11% |
| 2019 | 4.26 | -66.25% |
| 2018 | 12.64 | -30.58% |
| 2017 | 18.20 | 4.88% |
| 2016 | 0.37 | -82.16% |
| 2015 | 2.05 | -17.06% |
The current Current Ratio of Advicenne S.A. (ALDVI.PA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
1.96
5-year avg
2.09
10-year avg
4.79
Advicenne S.A.’s Current Ratio is greater than Poxel S.A. (0.34), greater than GenSight Biologics S.A. (0.24), less than THX Pharma (0.70), less than Nicox S.A. (6.62), less than genOway S.A. (2.50), greater than Valerio Therapeutics S.A. (0.25), less than Aelis Farma S.A. (3.18), less than Valbiotis S.A. (3.04), less than NFL Biosciences S.A. (1.27), greater than Ikonisys S.A. (0.30),
| Company | Current Ratio | Market cap |
|---|---|---|
| 0.34 | $12.46M | |
| 0.24 | $19.65M | |
| 0.70 | $17.33M | |
| 6.62 | $24.60M | |
| 2.50 | $23.25M | |
| 0.25 | $57.34M | |
| 3.18 | $14.64M | |
| 3.04 | $16.75M | |
| 1.27 | $14.19M | |
| 0.30 | $23.68M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Advicenne S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Advicenne S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Advicenne S.A.'s Current Ratio?
How is the Current Ratio calculated for Advicenne S.A. (ALDVI.PA)?
What is the highest Current Ratio for Advicenne S.A. (ALDVI.PA)?
What is the 3-year average Current Ratio for Advicenne S.A. (ALDVI.PA)?
What is the 5-year average Current Ratio for Advicenne S.A. (ALDVI.PA)?
How does the current Current Ratio for Advicenne S.A. (ALDVI.PA) compare to its historical average?